The global Parkinson’s disease drugs market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson’s disease. According to a report published by Fortune Business Insights, titled “Parkinson’s Disease Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 4,500.0 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,383.2 Mn by 2026, thereby exhibiting a CAGR of 8.1%.
Increasing usage approvals are contributing to the growth of the global Parkinson’s disease drugs market. The Food and Drug Administration recently cleared two new drugs for the treatment of Parkinson’s disease. The drug approvals for Rytary and Duopa will emerge as breakthroughs in the healthcare industry.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655
The report offers an elaborative analysis of numerous factors affecting the global Parkinson’s Disease Drugs Market. These include opportunities, growth drivers, threats, key developments, and restraints. In addition to this, the report can further help in analyzing, segmenting, and defining the market based on different segments. It strategically analyzes several strategies such as product innovations, mergers, alliances, joint ventures, and acquisitions adopted by players in the industry.
Leading Players operating in the Parkinson’s Disease Drugs Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Novartis
- Orion Pharma Ltd
- UCB S.A
- Teva Pharmaceutical Industries Ltd.
- Vertical Pharmaceuticals, LLC
- ACADIA Pharmaceuticals Inc.
- Impax Laboratories, Inc.
- Lundbeck A/S.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/parkinson-s-disease-drugs-market-100655
Key questions answered in the report:
What will the market growth rate of Parkinsons Disease Drugs Market in 2026?
What are the key factors driving the global Parkinsons Disease Drugs Market?
Who are the key manufacturers in Parkinsons Disease Drugs Market space?
What are the market opportunities, market risk and market overview of the Parkinsons Disease Drugs Market?
What are sales, revenue, and price analysis of top manufacturers of Parkinsons Disease Drugs Market?
Who are the distributors, traders and dealers of Parkinsons Disease Drugs Market?
What are the Parkinsons Disease Drugs Market opportunities and threats faced by the vendors in the global Robotic Surgical Procedures industry?
What are sales, revenue, and price analysis by types and applications of Parkinsons Disease Drugs Market?
What are sales, revenue, and price analysis by regions of Robotic Surgical Procedures industry?
AbbVie gets FDA Nod for Orphan Drug ‘Duopa’
The report includes an in-depth analysis of various drug approvals and their effect on the global market. In addition to the clearance for Rytary, the FDA approved another drug in the same year which was also associated with the treatment of Parkinson’s disease. ‘AbbVie’, a pharmaceutical company, announced that it had received approval for the commercialization of its ‘Duopa’. The duopa can be used for treating fluctuations in patients diagnosed with advanced Parkinson’s disease. The Duopa was classified as an orphan drug as it is used to treat a rare disease that is affecting fewer than 200,000 people in the United States. Fortune Business Insights has predicted that the aforementioned drug approvals may have a direct impact on the vendor scale. Competitors are likely to be encouraged by the approvals for Parkinson’s disease drugs. This, in turn, is likely to favor growth of the global market in the coming years.
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Trends
- Key Insights
- Prevalence of Parkinson’s Disease – For Key Countreis, 2018
- Regulatory Scenario – For Key Countries
- Patent Snapshot
- New Product Launch
- Pipeline Analysis
- Key Industry Developments – Mergers, Acquisitions and Partnerships
- Global Parkinson’s Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Decarboxylase Inhibitors
- Dopamine Agonists
- Monoamine Oxidase Type B (MAO-B) Inhibitors
- Catechol-O-Methyltransferase (COMT) Inhibitors
- Others
- Market Analysis, Insights and Forecast – By Route of Administration
- Oral
- Injection
- Transdermal
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Parkinson’s Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
- Key Findings / Summary
- Market Analysis – By Drug Class
- Decarboxylase Inhibitors
- Dopamine Agonists
- Monoamine Oxidase Type B (MAO-B) Inhibitors
- Catechol-O-Methyltransferase (COMT) Inhibitors
- Others
- Market Analysis – By Route of Administration
- Oral
- Injection
- Transdermal
- Market Analysis – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market Analysis – By Country
- S.
- Canada
Market Segmentation:
By Drug Class
- Decarboxylase Inhibitors
- Dopamine Agonists
- Monoamine Oxidase Type B (MAO-B) Inhibitor
- Catechol-O-Methyltransferase (COMT) Inhibitors
- Others
By Route of Administration
- Oral
- Injection
- Transdermal
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Reasons to Purchase this Report:
- Comprehensive analysis of the Parkinson’s Disease Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/parkinson-s-disease-drugs-market-100655
KEY QUESTIONS ANSWERED:
- What are the key technological and Parkinson’s Disease Drugs Market trends shaping the market?
- What are the key opportunities in the market?
- What are the key companies operating in the market?
- Which company accounted for the highest market share?
- Why Choose Fortune Business Insights?
- What is the market size and growth rate of the global and regional market by various segments?
- What is the market size and growth rate of the market for selective countries?
- Which region or sub-segment is expected to drive the market in the forecast period?
- What Factors are estimated to drive and restrain the Parkinson’s Disease Drugs Market growth?
